{"id":758624,"date":"2025-08-21T19:29:01","date_gmt":"2025-08-21T19:29:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=758624"},"modified":"2025-08-21T19:29:01","modified_gmt":"2025-08-21T19:29:01","slug":"nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-clinical-companies-therapies-pipeline-arcus-biosciences-akeso-biopharma-biotheus-glaxosmithkline-astrazeneca-pfizer-shandong-boan","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/nucleic-acid-and-gene-therapies-in-neuromuscular-disorders-clinical-companies-therapies-pipeline-arcus-biosciences-akeso-biopharma-biotheus-glaxosmithkline-astrazeneca-pfizer-shandong-boan_758624.html","title":{"rendered":"Nucleic Acid and Gene Therapies in Neuromuscular Disorders Clinical, Companies, Therapies, Pipeline | Arcus Biosciences, Akeso Biopharma, Biotheus, GlaxoSmithKline, AstraZeneca, Pfizer, Shandong Boan"},"content":{"rendered":"
\n
\"Nucleic<\/a><\/div>\n
\n
Nucleic Acid and Gene Therapies in Neuromuscular Disorders Clinical Trials<\/div>\n<\/div>\n<\/div>\n
DelveInsight\u2019s, \u201cPD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) – Pipeline Insight, 2025\u201d report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in PD-1 Non-Small Cell Lung Cancer (PD-1+ NSCLC) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.<\/div>\n

DelveInsight highlights that the Nucleic Acid and Gene Therapies pipeline for Neuromuscular Disorders includes over 25 major companies actively working on more than 30 investigational therapies.<\/p>\n

Nucleic Acid and Gene Therapies in Neuromuscular Disorders Overview:<\/strong><\/p>\n

Lung cancer continues to be one of the top causes of cancer-related deaths globally and is generally associated with a poor prognosis. The introduction of immune checkpoint inhibitors targeting programmed death-1 (PD-1) and its ligand PD-L1 has significantly changed the treatment landscape for non-small cell lung cancer (NSCLC). Blocking the PD-1\/PD-L1 pathway has demonstrated strong therapeutic benefits and improved survival outcomes in both preclinical and clinical studies for patients with locally advanced or metastatic NSCLC.<\/p>\n

PD-1 is a type I transmembrane protein found on T cells, B cells, natural killer cells, activated monocytes, and dendritic cells. Its ligands, PD-L1 and PD-L2, are also type I transmembrane proteins but have different expression patterns. PD-L1 is expressed on immune cells such as T cells, B cells, dendritic cells, and macrophages, as well as on various nonhematopoietic and tumor cells. Both PD-1 and its ligands comprise a signal sequence, an immunoglobulin (Ig) domain, transmembrane regions, and a short cytoplasmic tail.<\/p>\n

Binding of PD-1 to PD-L1 or PD-L2 triggers phosphorylation of two intracellular tyrosine residues, which recruits the phosphatases SHP-1 and SHP-2. These phosphatases interact with PD-1’s ITIM and ITSM motifs, ultimately inhibiting antigen receptor signaling. While this PD-1\/ligand interaction suppresses effector T-cell function, the binding of B7-1\/B7-2 to CD28 stimulates T-cell proliferation.<\/p>\n

Request for a detailed insights report on Nucleic Acid and Gene Therapies in Neuromuscular Disorders pipeline insights<\/a><\/strong><\/p>\n

“Nucleic Acid and Gene Therapies in Neuromuscular Disorders Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Nucleic Acid and Gene Therapies in Neuromuscular Disorders Therapeutics Market.<\/p>\n

Key Takeaways from the Nucleic Acid and Gene Therapies in Neuromuscular Disorders Pipeline Report<\/strong><\/p>\n